These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18980994)

  • 1. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.
    Chao DL; Sanchez CA; Galipeau PC; Blount PL; Paulson TG; Cowan DS; Ayub K; Odze RD; Rabinovitch PS; Reid BJ
    Clin Cancer Res; 2008 Nov; 14(21):6988-95. PubMed ID: 18980994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression.
    Reid BJ; Sanchez CA; Blount PL; Levine DS
    Gastroenterology; 1993 Jul; 105(1):119-29. PubMed ID: 8514029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
    Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
    Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
    Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
    Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
    Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities.
    Palanca-Wessels MC; Barrett MT; Galipeau PC; Rohrer KL; Reid BJ; Rabinovitch PS
    Gastroenterology; 1998 Feb; 114(2):295-304. PubMed ID: 9453489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.
    Galipeau PC; Cowan DS; Sanchez CA; Barrett MT; Emond MJ; Levine DS; Rabinovitch PS; Reid BJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7081-4. PubMed ID: 8692948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
    Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
    Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
    Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
    Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
    Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus.
    Barrett MT; Pritchard D; Palanca-Wessels C; Anderson J; Reid BJ; Rabinovitch PS
    Cancer Res; 2003 Jul; 63(14):4211-7. PubMed ID: 12874028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA; Remotti H; Baergen RN; Altorki NK
    Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression to cancer in Barrett's esophagus is associated with genomic instability.
    Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
    Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
    Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
    J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.